Navigation Links
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
Date:2/4/2009

-Preliminary Data Show Seven of 17 Evaluable Patients Achieved an Objective Tumor Response by End of Four Treatment Cycles-

TUSTIN, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that its lead product candidate bavituximab achieved the primary efficacy endpoint in the first stage of its ongoing Phase II clinical trial in patients with non-small cell lung cancer (NSCLC). The open-label, Simon two-stage study is designed to evaluate the safety and efficacy of the combination of bavituximab with the chemotherapy drugs carboplatin and paclitaxel in NSCLC patients. Seventeen of the 21 patients enrolled in Stage A were deemed evaluable for tumor response by the end of four treatment cycles, with six patients achieving partial tumor responses and one patient achieving a complete tumor response, according to RECIST criteria. These preliminary results exceed the pre-specified benchmark criteria established for enrolling an additional 28 patients in Stage B of this trial, up to a total of 49 patients.

"We are very pleased with the promising early results from this pilot Phase II lung cancer trial and will now move forward to initiate the second stage of the study," said Steven W. King, president and CEO of Peregrine. "We are encouraged by the number of tumor responses seen at this early time point of approximately 12 weeks in patients with NSCLC, a leading cause of cancer deaths that responds poorly to current treatments. As these patients continue on treatment, we will be assessing them for further signs of anti-tumor activity, and we look forward to sharing more data from this study as patient treatment and follow-up progress."

The primary objective of the multi-center Phase II clinical trial in patients with previously untreated locally advanced or metastatic NS
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
2. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
3. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
4. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
5. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
6. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
7. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
8. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
10. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
11. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 26, 2014 "Ischemic ... H2, 2014" provides data on the Ischemic Stroke ... provides elemental information and data relating to the ... , View full global Ischemic Stroke Research Report ... an overview of the trial numbers and their ...
(Date:7/25/2014)... Research and Markets  has announced ... 2014-2018" report to their offering. ... or Metabonomics is the scientific study of chemical ... experimental technique that is being widely used in ... small molecules that are present in blood, urine, ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Lawrence Livermore ... to Thomson Reuters list of " The World's Most ... part of the 3,000 researchers who were identified by ... recognize those who published the highest-impact work (2002-2012 and ... papers on combustion modeling . , "This recognition ...
(Date:7/25/2014)... Sinovac Biotech Ltd. (Nasdaq: SVA ), a leading ... today announced that it will release its unaudited financial results ... close on Thursday, August 14, 2014 EDT. The Company will ... Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, August ... the Company,s financial results and provide an update on recent ...
Breaking Biology Technology:Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... Advancements in technology continue at an accelerated pace, but ... new tech jobs for workers here in the United ... in the technology equation. We need to identify what ... to create the environment that fosters new jobs for ...
... makes you smile, and wish youd been in that basement in ... has come from two brothers working on a game on their ... the nation. Now with 95 employees and numerous hit games, Raven ... and Steve Raffel, brothers who had backgrounds in art, decided to ...
... Germany has often been regarded as the economic motor of ... just south of Scandinavia, to the east of the U.K. ... west of the east European countries of Poland, the Czech ... it has not only one of Europes largest populations but ...
Cached Biology Technology:Are U.S. Tech Jobs in Jeopardy? 2Are U.S. Tech Jobs in Jeopardy? 3Its All Fun And Games in Madison - Raven Software Celebrates 15 Anniversary 2Its All Fun And Games in Madison - Raven Software Celebrates 15 Anniversary 3German Life Science Oktoberfest Comes to the Midwest 2German Life Science Oktoberfest Comes to the Midwest 3German Life Science Oktoberfest Comes to the Midwest 4German Life Science Oktoberfest Comes to the Midwest 5German Life Science Oktoberfest Comes to the Midwest 6
(Date:7/28/2014)... a new study suggest two ways to effectively address the ... in obese women, compared to women of a normal body ... researchers say, but as the population has increased in weight, ... obese women. Studies have consistently found that obesity has a ... in turn affect how well the pill prevents pregnancy. ...
(Date:7/28/2014)... 28, 2014) Rice University researchers are using magnetic ... flexibility that can be used as microscale models for ... "bead-spring" polymers, introduced as theory in the 1950s, can ... and should be of interest to materials scientists who ... led by Rice chemical and biomolecular engineer Sibani Lisa ...
(Date:7/28/2014)... virus killers to prevent and treat HIV infection has ... response these molecules can arouse as they get rid ... at the Weizmann Institute and the National Institutes of ... these molecules interferons around the time of ... the disease. Their research appeared in Nature . ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Seeing is bead-lieving 2Interfering with interferon 2
... both in themselves and because they are most often cultivated ... impact on plant and animal diversity in those parts of ... What constitutes a dilemma for consumers wishing to shop ecologically ... is also common, the impact on diversity is negative. ...
... are determining ways to speed the return of residents ... The first step is providing better, more ... builders, architects and others says Dr. Dave Tilotta, associate ... the first part of a multi-phase study examining the ...
... COLUMBIA, Mo. Current arthritis medications can ease ... disease requires more aggressive treatments: use of very ... Missouri researchers hope to find new therapeutic targets ... proteins that, if interrupted, may prevent arthritis pain ...
Cached Biology News:Coffee cultivation good for diversity in agrarian settlements but not in forests 2Defying the disaster: Researcher explores resilient housing 2Inhibiting proteins may prevent cartilage breakdown in arthritis patients 2
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: